BPC-157 vs Larazotide

BPC-157 is believed to accelerate angiogenesis and upregulate growth hormone receptors locally at injury sites. It appears to promote fibroblast migration and collagen synthesis, contributing to faster tissue remodelling. Animal studies suggest systemic effects via modulation of the dopaminergic and serotonergic systems, though human data remain limited.

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide (15 amino acids) derived from a gastric mucosal protein sequence, investigated in preclinical models for tissue repair, wound healing, and gastrointestinal protection. In animal models, BPC-157 promotes angiogenesis, upregulates growth hormone receptor expression in tendon fibroblasts, and modulates nitric oxide signaling, contributing to the tissue-reparative effects observed across rodent studies predominantly from the Sikiric research group in Zagreb. Published research consists almost entirely of rodent and in vitro studies; no human pharmacokinetic, safety, or efficacy trials have been indexed in PubMed, representing a significant gap between its widespread use as a research compound and the quality of available evidence. BPC-157 has no FDA approval and is not approved for human use in any major Western jurisdiction; it is classified as a research compound only, and all proposed clinical benefits remain unvalidated outside of animal model contexts. BPC-157 is a component of the GLOW research blend (BPC-157 + TB-500 + GHK-Cu), a combination studied in research contexts for complementary effects on tissue repair, angiogenesis, and musculoskeletal recovery. Research on BPC-157 and TB-500 combinations proposes additive tissue-reparative signaling through complementary mechanisms — BPC-157 via nitric oxide pathway modulation and GH receptor upregulation in tendon fibroblasts, TB-500 via actin cytoskeleton regulation and cell migration support — though published human evidence for combination protocols does not exist, and no standardized human protocol has been established for BPC-157 or any of its combination blends. BPC-157 is studied across multiple administration routes in research contexts. Subcutaneous injection is the most commonly referenced route in preclinical tissue repair literature. Oral and capsule delivery is of particular research interest given BPC-157's gastric mucosal origin and PepT1 transporter recognition — animal studies show systemic effects following oral administration, and oral BPC-157 formulations are the subject of active preclinical GI research. Nasal spray delivery is an emerging format studied in combination blends such as BPC-157 + TB-500 nasal spray preparations, where the nasal mucosal route may offer a needle-free alternative; published pharmacokinetic data for nasal BPC-157 in humans is not available. Where to get BPC-157: BPC-157 is available through licensed telehealth platforms, compounding pharmacies, and some peptide-focused clinics in the United States and internationally. Because BPC-157 requires a prescription when dispensed by a licensed compounding pharmacy, access typically involves a consultation with a clinician who specializes in peptide or regenerative medicine. PeptideBase maintains a directory of verified providers — including telehealth platforms that conduct remote consultations — for those researching where to find BPC-157 through supervised channels. BPC-157 formulation and translational status BPC-157 is supplied as a lyophilized powder; reconstituted formulations are available through research-peptide suppliers. A 2026 review in Pharmaceutics (PMID 42198317) identified multiple unresolved biopharmaceutical challenges: BPC-157 currently lacks an approved formulation, a validated dosing regimen across any administration route, and completed Phase II clinical trials. The review noted 'a disconnect between its pharmacokinetic and pharmacodynamic properties that have impeded clinical advancement,' with multiple regulatory and translational barriers continuing to prevent clinical progression. These gaps apply equally to subcutaneous, oral, and intranasal routes — no route has an established human dosing regimen validated by clinical data. BPC-157 oral — capsule form and GI applications BPC-157 is one of the few peptides with research support for both injectable and oral routes of administration. Unlike most peptides, which are rapidly degraded by proteases and gastric acid, BPC-157 demonstrates relative stability in the GI environment — a property attributed to its origin as a fragment of the gastric mucosal protein BPC (Body Protection Compound), where resistance to gastric degradation is functionally relevant. Oral BPC-157 in capsule form has been studied specifically in gastrointestinal contexts: research covers gastric ulcer healing, inflammatory bowel models, leaky gut repair, and esophageal damage. For gut-specific conditions, oral administration may be preferable to injectable because the peptide contacts damaged tissue directly during transit through the GI tract. Oral vs injectable BPC-157: The distinction matters for application. Injectable (subcutaneous or intramuscular) BPC-157 is preferred for systemic applications — tendon healing, ligament repair, nerve regeneration, and muscle injury — where the compound needs to enter circulation. Optimal dosing for either route has not been established in human clinical trials; published preclinical models inform research-community practice but do not constitute a validated human regimen. Oral bioavailability for systemic effects is lower than injectable, though some research suggests even oral dosing produces measurable systemic peptide levels. Enteric-coated capsules are sometimes used to protect the peptide through gastric transit. Research on comparative efficacy between routes for systemic indications (vs GI-specific) is limited in human data. BPC-157 nasal spray — intranasal delivery BPC-157 can be prepared as an intranasal spray by dissolving lyophilized powder in bacteriostatic water or saline to the desired concentration. Intranasal BPC-157 is used in research contexts primarily for CNS applications — where direct mucosal absorption to the brain via the olfactory pathway is proposed to increase CNS availability relative to systemic injection — and as a systemic administration route for users seeking an alternative to subcutaneous injection. No validated human dosing protocol exists for intranasal BPC-157 administration. BPC-157 and TB-500 nasal spray blends are a combined formulation in the research peptide market, allowing co-administration via a single delivery mechanism. Independent human research specifically evaluating intranasal BPC-157 pharmacokinetics or efficacy relative to subcutaneous injection is limited; this delivery route is derived from research-community practice and preclinical models rather than comparative clinical data.

Synthetic octapeptide that prevents zonulin-mediated tight junction opening; maintains intestinal epithelial barrier integrity

Larazotide acetate (AT-1001) is a synthetic octapeptide zonulin antagonist that reduces intestinal permeability by blocking zonulin-mediated disassembly of intestinal epithelial tight junctions, studied as an adjunctive treatment to reduce symptom burden in celiac disease patients during inadvertent or deliberate gluten exposure. By inhibiting zonulin receptor signaling, larazotide prevents the disruption of tight junction proteins — including occludin and claudins — that would otherwise permit immunogenic gluten peptides to traverse the epithelial barrier and trigger the CD4+ T-cell-mediated mucosal injury characteristic of active celiac disease. A Phase 2 randomized, double-blind trial published in The American Journal of Gastroenterology demonstrated that larazotide acetate reduced activation of celiac disease during gluten challenge; however, the Phase 3 trial published in Gastroenterology, designed to evaluate larazotide for persistent symptoms in celiac disease patients already following a gluten-free diet, did not meet its primary endpoint. Larazotide has not received FDA approval; no NDA has been filed following the Phase 3 outcome, and it remains an investigational compound with no approved indication.